Cargando…

Preliminary study on the relationship among stem cell markers, drug resistance and PI3K signaling pathway in multiple myeloma (MM) cell

BACKGROUND: This study aims to explore the mechanism of drug resistance in multiple myeloma (MM). METHODS: In this study, the possible mechanism of chemotherapeutic tolerance was preliminarily explored from two aspects: (I) the changes in cell morphology, cell cycle, cell apoptosis, stem cell marker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ning, Liu, Bingshan, Wang, Danyang, Song, Yongping, Luo, Suxia, Fang, Baijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798546/ https://www.ncbi.nlm.nih.gov/pubmed/35117704 http://dx.doi.org/10.21037/tcr-19-2116

Ejemplares similares

The Synchronous Presence of Multiple Myelomas and Other Primary Malignant Tumors: Case Series with Literature Review
por: Li, Ning, et al.
Publicado: (2020)

A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line
por: LI, WEI, et al.
Publicado: (2015)

P860: CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS
por: Vigliotta, Ilaria, et al.
Publicado: (2023)

Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
por: Heinemann, Luca, et al.
Publicado: (2022)

Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells
por: Grad, Jennifer M., et al.
Publicado: (2001)

Specific roles for the PI3K and the MEK–ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model
por: Menu, E, et al.
Publicado: (2004)

Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Inhibitor of Apoptosis Proteins (IAPs) as therapeutic targets in Multiple Myeloma (MM)
por: Ramakrishnan, Vijay, et al.
Publicado: (2014)

The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
por: Hernández-Rivas, José-Ángel, et al.
Publicado: (2022)

The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease
por: Lungu, Oxana, et al.
Publicado: (2023)

PB2140: EVALUATION OF EARLY RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS
por: Gkioka, Annita-Ioanna, et al.
Publicado: (2023)

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination
por: Sahin, I, et al.
Publicado: (2014)

Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cells
por: Ettari, Roberta, et al.
Publicado: (2019)

miR-144-3p Suppresses Osteogenic Differentiation of BMSCs from Patients with Aplastic Anemia through Repression of TET2
por: Li, Ning, et al.
Publicado: (2019)

Human leukocyte antigen-DRB1 gene polymorphism and aplastic anemia: A meta-analysis
por: Liang, Lijie, et al.
Publicado: (2023)

Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM)
por: Tibullo, Daniele, et al.
Publicado: (2016)

Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway
por: Zhou, Yan, et al.
Publicado: (2022)

Study of the missing-mass spectra in the reactions $\pi^{-}d \rightarrow K^{+} + MM$ and $K^{-}d \rightarrow \pi^{+} + MM$ at 1.4 GeV/c to search for strange dibaryon states
por: D'Agostini, Giulio, et al.
Publicado: (1981)

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
por: Schmitt, Michael, et al.
Publicado: (2016)

Connect MM Registry as a national reference for United States multiple myeloma patients
por: Ailawadhi, Sikander, et al.
Publicado: (2019)

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
por: Bahlis, Nizar J., et al.
Publicado: (2023)

P1685: PATIENTS’ PREFERENCES FOR MULTIPLE MYELOMA (MM) TREATMENT INITIATION AND DISCONTINUATION IN THE US
por: Binder, Adam F., et al.
Publicado: (2023)

Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM)
por: Huang, Yuejiao, et al.
Publicado: (2019)

TGF-β induces growth suppression in multiple myeloma MM.1S cells via E2F1
por: Liu, Xialei, et al.
Publicado: (2021)

The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment
por: Jurczyszyn, Artur, et al.
Publicado: (2015)

PB1959: ESTABLISHMENT OF A NEW MULTIPLE MYELOMA (MM) RESEARCH MODEL USING MAGNETICALLY EMPOWERED TUMOR CELLS AND NK CELLS
por: Wang, Z., et al.
Publicado: (2022)

Clinical trials of CAR-T cells in China
por: Liu, Bingshan, et al.
Publicado: (2017)

PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment
por: Piddock, R E, et al.
Publicado: (2017)

Ectopic MicroRNA-150-5p Transcription Sensitizes Glucocorticoid Therapy Response in MM1S Multiple Myeloma Cells but Fails to Overcome Hormone Therapy Resistance in MM1R Cells
por: Palagani, Ajay, et al.
Publicado: (2014)

MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma
por: Du, Juan, et al.
Publicado: (2015)

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
por: Ho, Matthew, et al.
Publicado: (2021)

MM-219: Outcome of COVID-19 Among Patients with Multiple Myeloma at the Armenian Hematology Center
por: Sahakyan, Lusine, et al.
Publicado: (2021)

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
por: Lesokhin, Alexander M., et al.
Publicado: (2023)

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial
por: Huhn, S, et al.
Publicado: (2017)

CD138(-) multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient
por: Wu, Dong, et al.
Publicado: (2020)

Multiple myeloma cancer stem cells
por: Gao, Minjie, et al.
Publicado: (2016)

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_peo65669bm02ghqq4fc0ith6r8